13 February 2017 - We are pausing our commercialisation efforts in order to meet with Duchenne community leaders and explain our commercialisation plans, review their concerns, discuss all options, and move forward with commercialisation based on the resulting plan of action.

I want to thank you all for your support and encouragement over the last several years as Marathon worked to bring Emflaza (deflazacort) through the rigorous FDA approval process so patients in the United States would finally have access to this medicine and an understanding of this product. We know this has been a decades-long goal of the Duchenne community and we are proud to have been your partners in this effort.

Read open letter from Marathon Pharmaceuticals CEO